Annual report pursuant to Section 13 and 15(d)

Acquisitions, Investments, and Licenses - Schedule of EirGen Purchase Price Allocation (Details)

v3.3.1.900
Acquisitions, Investments, and Licenses - Schedule of EirGen Purchase Price Allocation (Details) - USD ($)
$ in Thousands
Dec. 31, 2015
 [1]
May. 31, 2015
Dec. 31, 2014
 [1]
Dec. 31, 2013
Business Acquisition [Line Items]        
Goodwill $ 743,348   $ 224,292 $ 226,373
EirGen Pharma Limited        
Business Acquisition [Line Items]        
Current assets   $ 11,795    
Intangible assets   38,634    
Goodwill   83,373    
Property, plant and equipment   8,117    
Other assets   1,232    
Accounts payable and other liabilities   (6,254)    
Deferred tax liability   3,131    
Total purchase price   133,766    
Cash and cash equivalents   5,500    
Accounts receivable   2,700    
Inventory   2,200    
Other current assets   1,400    
IPR&D assets | EirGen Pharma Limited        
Business Acquisition [Line Items]        
Intangible assets   560    
Customer relationships | EirGen Pharma Limited        
Business Acquisition [Line Items]        
Intangible assets   34,155    
Currently marketed products | EirGen Pharma Limited        
Business Acquisition [Line Items]        
Intangible assets   $ 3,919    
[1] As of December 31, 2014, total assets include $7.6 million and total liabilities include $12.1 million related to SciVac Ltd (“SciVac”). SciVac was a consolidated variable interest entity which we deconsolidated in July 2015. Refer to Note 4. SciVac’s consolidated assets were owned by SciVac and SciVac’s consolidated liabilities had no recourse against us.